New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 16, 2014
07:15 EDTTBIOTransgenomic board approves reverse stock split ratio
Transgenomic, announced that it has filed an application for listing its common shares on the NASDAQ. The company's proposed listing on the NASDAQ is subject to review by NASDAQ and dependent upon the company meeting all relevant quantitative and qualitative listing criteria of NASDAQ. The company believes it currently meets all of NASDAQ's eligibility requirements with the exception of the minimum bid price requirement, which will be addressed by a reverse split of the company’s common stock. In addition Transgenomic also announced that its board has approved a 1-for-12 reverse split of its issued and outstanding shares of common stock, with a planned effective date of January 27. After giving effect to the reverse stock split, every 12 shares of the company's issued and outstanding common stock will automatically be combined into one share of the company's issued and outstanding common stock. After the reverse split, the number of shares outstanding will be reduced from approximately 88.3M shares to approximately 7.4M shares. In connection with the reverse split, stockholders will not receive fractional post-reverse stock split shares. Instead, holders will receive cash in lieu of fractional shares.
News For TBIO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 30, 2014
07:06 EDTTBIOTransgenomic, University of Melbourne announce collaboration
Transgenomic announced a research agreement with the University of Melbourne to conduct additional clinical validation studies of its Multiplexed ICE COLD-PCRTM technology. The new study will be conducted using DNA isolated from pre-treatment tumor biopsies from patients enrolled in clinical trials. It aims to determine the prevalence and clinical significance of ultra-low frequency mutations that would otherwise go undetected by NGS or Sanger sequencing-based methodologies. In the next phase of the project, Transgenomic expects to conduct further studies with University of Melbourne researchers to validate the use of MX-ICP to accurately detect tumor mutations using blood or plasma. Transgenomic’s MX ICE COLD-PCR technology is exclusively licensed from the Dana-Farber Cancer Institute.
07:04 EDTTBIOTransgenomic Inc reports Q3 EPS (5c), may not compare to one estimate (58c)
Subscribe for More Information
October 20, 2014
07:10 EDTTBIOAmerican Society of Human Genetics to hold annual meeting
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use